Tiziana Life Sciences Ltd (FRA:0RP)
Germany · Delayed Price · Currency is EUR 1.540
+0.010 (0.65%)
At close: Nov 28, 2025
Tiziana Life Sciences Company Description
Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States.
The company’s lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn’s, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.
It is also developing TZLS-501, a fully human mAb targeting the IL-6 receptor for use in the treatment of inflammatory and oncology indications.
Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.
Tiziana Life Sciences Ltd
| Country | Bermuda |
| Founded | 1998 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 9 |
| CEO | Ivor Elrifi |
Contact Details
Address: 14/15 Conduit Street London, W1S 2XJ United Kingdom | |
| Phone | 44 20 7495 2379 |
| Website | tizianalifesciences.com |
Stock Details
| Ticker Symbol | 0RP |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Ivor Elrifi | Chief Executive Officer |
| Keeren Shah | Chief Financial Officer |
| Keeren Shah | Chief Operating Officer |